Preliminary safety, pharmacokinetics and anti-tumor activity of BYL719, an alpha-specific PI3K inhibitor in combination with fulvestrant: Results from a phase i study

This article has no abstract
Epistemonikos ID: c1a0c0b654f26d1bdab7935a23d0abffdad88a92
First added on: Feb 06, 2025